Synthesis and pharmacological evaluation of dimer derivatives of the bradykinin receptor antagonist HOE-140

J Pept Res. 1998 Jul;52(1):1-14. doi: 10.1111/j.1399-3011.1998.tb00646.x.

Abstract

The synthesis and pharmacological evaluation of dimer derivatives of the C-terminal fragments of the potent bradykinin antagonist HOE-140, linked through their N-termini, were performed. The influence of peptide moiety length was studied using the succinyl moiety as a linker. Our attention focused on the dimer of the C-terminal tetrapeptide of HOE-140 (compound JMV 980), which displayed some inhibiting activity (IC50 = 247 nM) for bradykinin B2 receptors. Unexpectedly, it was orally active in inhibiting bradykinin-induced hypotension in the rat. Based on this tetrapeptide dimer model, we synthesized pseudotetrapeptide dimer bradykinin antagonists 29 and 33, which exhibited high affinity (Ki = 76 and 61 nM, respectively) for the human cloned B2 receptor. In addition, compound 29 inhibited bradykinin-induced contraction of the human umbilical vein giving a pKB value of 6.45. Compounds 29 and 33 were selective toward B2 receptors because they did not bind to the cloned human B1 receptor up to 10 microM.

MeSH terms

  • Animals
  • Antihypertensive Agents / chemical synthesis
  • Bradykinin / analogs & derivatives*
  • Bradykinin / pharmacology
  • Bradykinin Receptor Antagonists*
  • Dimerization
  • Humans
  • Molecular Structure
  • Muscle Contraction / drug effects
  • Muscle, Smooth, Vascular / drug effects
  • Peptides / chemistry*
  • Rats
  • Receptor, Bradykinin B2
  • Receptors, Bradykinin / chemistry*

Substances

  • Antihypertensive Agents
  • Bradykinin Receptor Antagonists
  • Peptides
  • Receptor, Bradykinin B2
  • Receptors, Bradykinin
  • icatibant
  • Bradykinin